UKCCCR trial to study the effect on breast cancer mortality of annual mammographic screening starting at age 40

ISRCTN	ISRCTN24647151
DOI	https://doi.org/10.1186/ISRCTN24647151
Protocol serial number	G9000793
Sponsor	Medical Research Council (MRC) (UK)
Funders	Medical Research Council (MRC) (UK), Long-term follow up funded by National Institute for Health Research (NIHR) / Health Technology Assessment (HTA)

Submission date: 06/04/2000
Registration date: 06/04/2000
Last edited: 19/08/2020

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Sue Moss
Scientific

Professor of Cancer Epidemiology
Centre for Cancer Prevention
Queen Mary University of London
Wolfson Institute of Preventive Medicine Charterhouse Square London
London
EC1M 6BQ
United Kingdom

Phone	+44 (0)207 882 5841
Email	s.moss@qmul.ac.uk

Study information

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title	UKCCCR trial to study the effect on breast cancer mortality of annual mammographic screening starting at age 40
Study acronym	The 'Age' trial
Study objectives	To determine the effectiveness of mammographic screening starting at age 40, compared with starting at age 50, in reducing mortality from breast cancer.
Ethics approval(s)	Ethics approval from Central London REC 98/2/40.
Health condition(s) or problem(s) studied	Breast cancer
Intervention	Women in the intervention group are offered annual screening by mammography until the year of their 48th birthday. Screening is by 2-view mammography at 1st screen and single view subsequently. All women in both intervention and control groups will be invited for screening in the NHSBSP between the age of 50-52.
Intervention type	Other
Primary outcome measure(s)	Deaths from breast cancer in women free of the disease at trial entry in the two groups. Information on prognostic factors of all breast cancers is also collected.
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	31/12/2010

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Female
Target sample size at registration	160000
Key inclusion criteria	Women aged 40-41 identified from Health Authorities registers
Key exclusion criteria	Women under care for breast cancer may be removed from the prior notification list by the GPs prior to randomisation
Date of first enrolment	30/07/1990
Date of final enrolment	31/12/2010

Locations

Countries of recruitment

United Kingdom
England

Study participating centre

Queen Mary University of London

London
EC1M 6BQ
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	09/12/2006		Yes	No
Results article	results	01/09/2015		Yes	No
Results article	results	01/04/2016		Yes	No
Results article	results	01/09/2020	19/08/2020	Yes	No
Protocol article	protocol	01/07/1999		Yes	No
Other publications	Implications of pathologist concordance	01/03/2002		Yes	No
Other publications	assessment of contamination in the control group:	01/04/2010		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes

Editorial Notes

19/08/2020: Publication reference added.
08/02/2016: Publication reference added.